CN100415225C - 肽类化合物用于治疗非神经性炎性疼痛的新用途 - Google Patents

肽类化合物用于治疗非神经性炎性疼痛的新用途 Download PDF

Info

Publication number
CN100415225C
CN100415225C CNB028067614A CN02806761A CN100415225C CN 100415225 C CN100415225 C CN 100415225C CN B028067614 A CNB028067614 A CN B028067614A CN 02806761 A CN02806761 A CN 02806761A CN 100415225 C CN100415225 C CN 100415225C
Authority
CN
China
Prior art keywords
pain
purposes
group
treatment
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028067614A
Other languages
English (en)
Chinese (zh)
Other versions
CN1498103A (zh
Inventor
N·塞尔维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ucb Pharma Inc
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100415225(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of CN1498103A publication Critical patent/CN1498103A/zh
Application granted granted Critical
Publication of CN100415225C publication Critical patent/CN100415225C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB028067614A 2001-03-20 2002-03-19 肽类化合物用于治疗非神经性炎性疼痛的新用途 Expired - Fee Related CN100415225C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106891.3 2001-03-20
EP01106891A EP1243262B1 (en) 2001-03-20 2001-03-20 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2008101283801A Division CN101332292B (zh) 2001-03-20 2002-03-19 肽类化合物用于治疗非神经性炎性疼痛的新用途

Publications (2)

Publication Number Publication Date
CN1498103A CN1498103A (zh) 2004-05-19
CN100415225C true CN100415225C (zh) 2008-09-03

Family

ID=8176844

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028067614A Expired - Fee Related CN100415225C (zh) 2001-03-20 2002-03-19 肽类化合物用于治疗非神经性炎性疼痛的新用途
CN2008101283801A Expired - Fee Related CN101332292B (zh) 2001-03-20 2002-03-19 肽类化合物用于治疗非神经性炎性疼痛的新用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008101283801A Expired - Fee Related CN101332292B (zh) 2001-03-20 2002-03-19 肽类化合物用于治疗非神经性炎性疼痛的新用途

Country Status (30)

Country Link
US (3) US6803481B2 (enExample)
EP (2) EP1243262B1 (enExample)
JP (1) JP4955906B2 (enExample)
KR (1) KR100773100B1 (enExample)
CN (2) CN100415225C (enExample)
AT (2) ATE327744T1 (enExample)
AU (1) AU2002257681C1 (enExample)
BR (1) BR0205823A (enExample)
CA (1) CA2419397C (enExample)
CY (3) CY1105533T1 (enExample)
CZ (1) CZ20032763A3 (enExample)
DE (3) DE60120104T2 (enExample)
DK (2) DK1243262T3 (enExample)
EA (1) EA007532B1 (enExample)
ES (2) ES2262567T3 (enExample)
FR (1) FR09C0041I2 (enExample)
HU (1) HUP0303600A3 (enExample)
IL (2) IL154087A0 (enExample)
LU (1) LU91590I2 (enExample)
MX (1) MXPA03008467A (enExample)
NL (1) NL300399I1 (enExample)
NO (1) NO20033629D0 (enExample)
NZ (1) NZ523865A (enExample)
PL (1) PL216213B1 (enExample)
PT (2) PT1243262E (enExample)
SI (2) SI1373300T1 (enExample)
SK (1) SK287539B6 (enExample)
UA (1) UA82645C2 (enExample)
WO (1) WO2002074784A2 (enExample)
ZA (1) ZA200300858B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001286763C1 (en) * 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
MX2007009070A (es) 2005-01-28 2007-09-12 Sanol Arznei Schwarz Gmbh (spm 927) para terapia supletoria de esquizofrenia.
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
ATE530175T1 (de) * 2006-06-08 2011-11-15 Ucb Pharma Gmbh Therapeutische kombination für schmerzhafte medizinische zustände
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2012084126A2 (en) 2010-12-02 2012-06-28 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
CN110478342A (zh) * 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (enExample) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
FI971412A7 (fi) * 1994-10-05 1997-04-04 Darwin Discovery Ltd Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (en) * 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
AU714980B2 (en) * 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP0997147B1 (en) 1997-07-08 2006-03-15 Ono Pharmaceutical Co., Ltd. Amino acid derivatives
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
US6509341B1 (en) 1997-10-31 2003-01-21 Abbott Laboratories Carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
ES2295048T3 (es) 1999-09-03 2008-04-16 Actelion Pharmaceuticals Ltd. Bis-sulfonamidas.
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
NZ524687A (en) 2000-08-17 2005-01-28 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
AU2001286763C1 (en) 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US6815451B2 (en) 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
WO2002088664A2 (en) 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
AU2003276201A1 (en) 2002-11-11 2004-06-03 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
DE60318749T2 (de) 2002-11-18 2009-01-22 Bioprospecting Nb Inc. Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
EP1589959A2 (en) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
EP1596844A2 (en) 2003-01-30 2005-11-23 Dynogen Pharmaceuticals Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
ATE428413T1 (de) 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASSESSMENTANDTREATMENTOFNEUROPATHICPAIN. JENSENTS.EUROPEANJOURNALOFNEUROLOGY,RAPID SCIENCEPUBLISHERS,,Vol.7 No.3. 2000 *

Also Published As

Publication number Publication date
EP1373300A2 (en) 2004-01-02
CN1498103A (zh) 2004-05-19
DK1243262T3 (da) 2006-10-02
NO20033629L (no) 2003-08-15
SI1373300T1 (sl) 2009-10-31
CY1109308T1 (el) 2012-01-25
EP1373300B1 (en) 2009-05-20
NO20033629D0 (no) 2003-08-15
US8053476B2 (en) 2011-11-08
NL300399I1 (en) 2009-10-01
CY2009013I1 (el) 2012-01-25
ES2326627T3 (es) 2009-10-16
EA007532B1 (ru) 2006-10-27
SK287539B6 (sk) 2011-01-04
HUP0303600A3 (en) 2011-11-28
AU2002257681C1 (en) 2008-02-21
HUP0303600A2 (hu) 2004-03-01
SK12832003A3 (sk) 2004-02-03
SI21170A (sl) 2003-10-31
JP2004524340A (ja) 2004-08-12
EP1243262A1 (en) 2002-09-25
HK1058368A1 (en) 2004-05-14
US20050085423A1 (en) 2005-04-21
AU2002257681B2 (en) 2007-06-07
FR09C0041I2 (enExample) 2010-01-22
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
LU91590I2 (fr) 2009-10-05
PT1373300E (pt) 2009-07-22
DE60120104D1 (de) 2006-07-06
DK1373300T3 (da) 2009-08-31
AU2002257681A2 (en) 2002-10-03
CA2419397A1 (en) 2002-09-26
CY1105533T1 (el) 2010-07-28
EP1243262B1 (en) 2006-05-31
US6803481B2 (en) 2004-10-12
PT1243262E (pt) 2006-10-31
MXPA03008467A (es) 2003-12-08
DE60120104T2 (de) 2006-09-21
WO2002074784A2 (en) 2002-09-26
US20070054962A1 (en) 2007-03-08
ATE327744T1 (de) 2006-06-15
CY2009013I2 (el) 2012-01-25
PL362985A1 (en) 2004-11-15
US20030171300A1 (en) 2003-09-11
KR100773100B1 (ko) 2007-11-02
ZA200300858B (en) 2003-07-09
EA200300932A1 (ru) 2004-04-29
IL154087A0 (en) 2003-07-31
ATE431833T1 (de) 2009-06-15
CZ20032763A3 (cs) 2004-01-14
ES2262567T3 (es) 2006-12-01
NZ523865A (en) 2004-12-24
BR0205823A (pt) 2003-10-21
WO2002074784A3 (en) 2002-11-21
KR20040004369A (ko) 2004-01-13
DE122009000053I1 (de) 2010-05-27
DE60232407D1 (de) 2009-07-02
CN101332292A (zh) 2008-12-31
JP4955906B2 (ja) 2012-06-20
CN101332292B (zh) 2012-06-20
IL154087A (en) 2010-05-17
CA2419397C (en) 2009-09-15
FR09C0041I1 (enExample) 2009-10-30

Similar Documents

Publication Publication Date Title
CN100415225C (zh) 肽类化合物用于治疗非神经性炎性疼痛的新用途
US5849737A (en) Compositions and methods for treating pain
JP4977297B2 (ja) トラマドール物質及び抗痙攣薬を含んで成る組成物
KR100557852B1 (ko) 이통증 또는 다른 여러가지 타입의 만성동통 또는 환상통을 치료하는데 쓰이는 의약 조성물
DE60127459T2 (de) Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz
JPH06502869A (ja) トラマドール物質およびアセトアミノフェンを含んでなる組成物並びにそれの使用
CA2781436C (en) Arachidonic acid analogs and methods for analgesic treatment using same
AU2002257681A1 (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
JP2008503533A (ja) 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用
US6166085A (en) Method of producing analgesia
EP0919244A2 (de) Kombinationspräparate für die Therapie von Tumoren
CA2817198C (en) Compositions and methods for treating hyperproliferative disorders
EP1977750A1 (en) Use of thioproline in body weight reduction treatments
KR20030074610A (ko) Ｐｃｐ 중독 및 ｐｃｐ 중독 관련 행동의 치료방법
DE102011108116A1 (de) Reserpin zur Behandlung von kognitiven Störungen des zentralen Nervensystems
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
HK1058368B (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
HK1049960A (en) Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: UCB PHARMA. CO., LTD.

Free format text: FORMER NAME: SCHWARZ PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: German Monheim

Patentee after: UCB Pharma Inc.

Address before: German Monheim

Patentee before: Schwarz Pharma AG

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080903

Termination date: 20140319